TY  - JOUR
AU  - Pickhardt, Marcus
AU  - Tassoni, Michele
AU  - Denner, Philip
AU  - Kurkowsky, Birgit
AU  - Kitanovic, Ana
AU  - Möhl, Christoph
AU  - Fava, Eugenio
AU  - Mandelkow, Eckhard
TI  - Screening of a neuronal cell model of tau pathology for therapeutic compounds.
JO  - Neurobiology of aging
VL  - 76
SN  - 0197-4580
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DZNE-2020-06834
SP  - 24-34
PY  - 2019
AB  - We have developed a cell-based phenotypic automated high-content screening approach for N2a cells expressing the pro-aggregant repeat domain of tau protein (tauRDΔK), which allows analysis of a chemogenomic library of 1649 compounds for their effect on the inhibition or stimulation of intracellular tau aggregation. We identified several inhibitors and stimulators of aggregation and achieved a screening reproducibility >85
KW  - Cell Line
KW  - Drug Evaluation, Preclinical: methods
KW  - Enzyme Inhibitors: pharmacology
KW  - Histone Deacetylase Inhibitors
KW  - Histone Deacetylases: pharmacology
KW  - Humans
KW  - Models, Biological
KW  - Protein Aggregation, Pathological: genetics
KW  - Protein Aggregation, Pathological: metabolism
KW  - Signal Transduction: genetics
KW  - Signal Transduction: physiology
KW  - Tauopathies: drug therapy
KW  - Tauopathies: genetics
KW  - Tauopathies: metabolism
KW  - p38 Mitogen-Activated Protein Kinases: antagonists & inhibitors
KW  - tau Proteins: metabolism
KW  - Enzyme Inhibitors (NLM Chemicals)
KW  - Histone Deacetylase Inhibitors (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - p38 Mitogen-Activated Protein Kinases (NLM Chemicals)
KW  - Histone Deacetylases (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30640040
DO  - DOI:10.1016/j.neurobiolaging.2018.11.026
UR  - https://pub.dzne.de/record/140512
ER  -